Special Issue

Plant Based Vaccines—A Powerhouse for Global Health 2.0

Message from the Guest Editors

Plants are emerging as powerful platforms for the production of biopharmaceuticals and industrial proteins. Plant-based vaccines, monoclonal antibodies and other therapeutic proteins show promise as inexpensive yet efficacious approaches to address global health. Vaccines made from plants are safe, easy to generate en masse and can be stored at ambient temperatures. These distinct properties make plant-based vaccines attractive alternatives for providing medicines which have previously been inaccessible and unaffordable to the poor in developing countries. In addition to this, plant-based vaccines can be stockpiled to guard against global pandemics such as Influenza and could been be employed in personalized medicine, such as addressing chronic diseases including cancer. Plant-based vaccines can therefore facilitate improvements in global health through multiple conduits. The following Special Issue explores various approaches used to generate plant-based vaccines, with examples provided in the context of global health.

Guest Editors

Dr. Kathleen Hefferon

Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 1A1, Canada

Dr. Srividhya Venkataraman

Virology Laboratory, Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 3B2, Canada

Deadline for manuscript submissions

closed (31 August 2021)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/si/81361

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed

mdpi.com/journal/vaccines

MDPI

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).